C2N Diagnostics
C2N Diagnostics is a St. Louis specialty diagnostics company developing proprietary blood-based tests for Alzheimer's disease using high-resolution mass spectrometry, serving healthcare providers, biopharmaceutical trial sponsors, and academic researchers globally.
- Company typePrivate
- Founded2007
- HeadquartersSaint Louis, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What C2N Diagnostics does
C2N Diagnostics is a St. Louis-based specialty diagnostics company developing blood-based tests for Alzheimer's disease and related neurodegenerative conditions. Founded in 2007 by Washington University neurologists Dr. David Holtzman and Dr. Randall Bateman, the company operates a CAP-accredited, CLIA-certified, ISO 13485:2016-compliant laboratory that performs tests using proprietary high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies licensed from the WashU Bateman Lab. Its clinical product portfolio includes PrecivityAD2™ (for patients aged 50+), PrecivityAD® (for patients aged 55+), and Precivity-ApoE™, with the research pipeline adding C2N eMTBR-tau243 and C2N %p-tau MAA assays focused on tau tangle pathology.
The company generates revenue primarily through per-test fees charged to healthcare professionals who order Precivity™ tests on behalf of patients; PrecivityAD is priced at $1,250 per test. Distribution extends across all 50 US states (enabled by the November 2025 NY State CLEP permit), Canada, the UK (via 2025 MHRA certification), and 18+ international markets through partnerships with Mayo Clinic Laboratories, Unilabs (75+ countries), and regional distributors across Asia-Pacific, Latin America, and the Middle East. A secondary revenue stream comes from bioanalytical services supporting pharmaceutical and academic clients, including Eisai's Alzheimer's programs and Phase 3 trials (Evoke/Evoke+) using C2N's eMTBR-tau243 assay for clinical trial recruitment and treatment monitoring.
Customer segments span healthcare providers (primary care, neurologists, memory care specialists), biopharmaceutical companies (clinical trial screening and treatment monitoring), and academic researchers (with over 200 published studies using C2N assays). The company is venture-backed with roughly $100M+ raised cumulatively across nine rounds from GHR Foundation, Samsung entities, ADDF, Eisai, and the Michael J. Fox Foundation, and is tripling its operational footprint via an 82,451-square-foot headquarters under construction at the Cortex Innovation District in St. Louis. C2N also disclosed a cybersecurity incident in April 2026 affecting employee email communications.
C2N Diagnostics firmographics
Firmographics- Name
- C2N Diagnostics
- Legal name
- C₂N Diagnostics, LLC
- Website
- https://c2n.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- C2N Diagnostics is a St. Louis specialty diagnostics company developing proprietary blood-based tests for Alzheimer's disease using high-resolution mass spectrometry, serving healthcare providers, biopharmaceutical trial sponsors, and academic researchers globally.
- Ownership category
- akta.pro rank
C2N Diagnostics industry classification
Industry- Product category
- Neurological Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industries
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG)
Keywords
Where C2N Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Saint Louis
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
C2N Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Clinical Laboratory Testing Services: C2N performs its Precivity™ blood tests in its CAP-accredited, CLIA-certified, ISO 13485:2016 compliant laboratory in St. Louis, Missouri. Healthcare professionals order tests for patients, and results are returned to inform medical management and treatment decisions. Revenue is generated per test performed.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | PrecivityAD Test - $1,250 per test |
Go-to-market motion1 record
Distribution channels10 records
Marketing channels6 records
C2N Diagnostics product offering
Product offeringCore offering
C2N Diagnostics develops and commercializes proprietary blood-based diagnostic tests for Alzheimer's disease and related neurodegenerative conditions using high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology. The core Precivity™ product line includes PrecivityAD®, PrecivityAD2™, and Precivity-ApoE™ clinical diagnostic tests, complemented by research-use-only tau assays (C2N eMTBR-tau243 and C2N %p-tau MAA) and bioanalytical services for pharmaceutical clinical trials. All clinical tests are processed in the company's CAP-accredited, CLIA-certified laboratory in St. Louis, Missouri, with global distribution through laboratory network and regional distribution partners.
Product overview
C2N Diagnostics offers a portfolio of blood-based diagnostic tests for Alzheimer's disease using proprietary high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies. The core clinical products include PrecivityAD2™ (for patients 50+), PrecivityAD® (for patients 55+), and Precivity-ApoE™. Research-use-only offerings include C2N eMTBR-tau243 plasma assay and C2N %p-tau MAA for tau pathology analysis. The company also provides bioanalytical services for clinical trials and pharmaceutical research partnerships. Tests are performed in the company's CAP-accredited, CLIA-certified, ISO 13485:2016 compliant facility in St. Louis, MO, and distributed globally through laboratory and distribution partnerships.
Differentiator
Problem solved
Functional benefit
Brands
- PrecivityAD: Blood test for Alzheimer's disease intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia undergoing evaluation for Alzheimer's disease or dementia
- PrecivityAD2
- Precivity-ApoE
Products and services
- PrecivityAD2™ Blood Test Blood test intended for patients aged 50 and older with signs or symptoms of mild cognitive impairment or dementia undergoing evaluation of Alzheimer's disease or dementia. Uses high-resolution mass spectrometry to detect amyloid plaques in the brain by measuring plasma p-tau217 and Aβ42/Aβ40 ratio. Performed in C2N's CAP-accredited, CLIA-certified laboratory.
- PrecivityAD® Blood Test Original blood test intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia undergoing evaluation of Alzheimer's disease or dementia. Uses mass spectrometry to measure amyloid proteins and apolipoprotein E genetic risk factors for Alzheimer's disease.
- Precivity-ApoE™ Blood Test Blood test indicated for adult patients for whom knowledge of apolipoprotein E2, E3, and E4 allele status may be informative for medical management and treatment decisions. Available through healthcare professional orders.
- C2N eMTBR-tau243 Plasma Assay Research Use Only plasma assay that selectively detects a specific region of tau (endogenous Microtubule Binding Region) shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer's disease. Used for disease staging, predicting progression, and monitoring treatment efficacy in research and clinical trial settings.
- C2N %p-tau MAA (Multi-Analyte Assay) Research Use Only p-tau multi-analyte assay using high-resolution mass spectrometry to precisely quantitate six analytes related to phosphorylated and non-phosphorylated tau forms (%p-tau181, %p-tau205, %p-tau217). Uses ratio of phosphorylated tau divided by non-phosphorylated tau to mitigate confounding factors such as age and medical comorbidities.
- C2N eMTBR-tau243 (CSF) Assay Cerebrospinal fluid (CSF) assay launched by C2N for detecting eMTBR-tau243 biomarkers, selectively identifying tau fragment regions for Alzheimer's research applications.
- Bioanalytical Services High-resolution mass spectrometry-based biomarker services for clinical trials, supporting pharmaceutical and biotechnology companies in maximizing quality and efficiency of neurodegeneration treatment trials. Assays have been used in over 200 Alzheimer's disease research studies globally.
Quantifiable outcome
- 91% accuracy, 90% sensitivity, 92% specificity versus amyloid PET imaging
- +4 more outcomes
Companies that use C2N Diagnostics
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
C2N Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
C2N Diagnostics partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered major, minor and core.
- SouthGeneticsmajorPartnership to enable broader access to Precivity® blood tests across Latin America and Caribbean including Argentina, Chile, Colombia, Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela.
- Codex GeneticsminorPartnership to launch PrecivityAD2 blood test in Hong Kong for early detection of Alzheimer's disease. Codex handles local regulatory compliance, distribution, and patient access.
- BeauBrain HealthcaremajorPartnership to launch PrecivityAD2 blood test in South Korea, making the test accessible to healthcare professionals for detecting amyloid plaques in patients 50 and older with cognitive impairment.
- Archerfish Precision DiagnosticsminorDistribution partner for PrecivityAD2 test in Singapore and Southeast Asian markets.
- Dr. Dangs LabminorDistribution partner for PrecivityAD2 test in India.
- Medical LinkminorDistribution partner for PrecivityAD2 test in Israel.
- Milenia LabsminorDistribution partner for PrecivityAD2 test in Costa Rica and Mexico.
- Accuserv Diagnostic CenterminorDistribution partner for PrecivityAD2 test in Philippines.
- Grupo FleuryminorInternational laboratory partner for C2N's Precivity™ diagnostic tests.
- HealiusminorInternational laboratory partner for C2N's Precivity™ diagnostic tests.
- MedifordminorResearch collaboration partner for Precivity™ Alzheimer's blood test expansion in Japan.
- Splash ClinicalminorPartnership to transform global clinical trial recruitment for Alzheimer's disease using Precivity™ blood tests to identify eligible patients for clinical trials.
- The Michael J. Fox FoundationcoreResearch partnership to uncover new links between Parkinson's disease, Lewy Body Dementia, and Alzheimer's disease using C2N's biomarker tests.
- UnilabsmajorGlobal partnership to make Precivity™ blood tests available across Unilabs' laboratory network in 75+ countries, advancing brain health diagnostics internationally.
- Mayo Clinic LaboratoriesmajorC2N's Precivity™ tests offered through Mayo Clinic Laboratories, providing access through one of the most respected laboratory networks in the United States.
Scale indicators10 records
Recent moves7 records
Expansion highlights7 records
C2N Diagnostics competitors and assessment
Company assessmentDirect peers
- Quanterix: Quanterix operates a single-molecule array (Simoa) ultra-sensitive protein detection platform used by researchers and clinical labs for blood-based biomarkers, including neurodegenerative disease assays. Directly comparable to C2N in that it sells biomarker testing services and immunoassay-based kits to pharma and academic researchers pursuing early AD detection and other neurology applications.
- ALZpath: ALZpath developed a proprietary p-tau217 antibody and offers a blood-based Alzheimer's diagnostic test as a laboratory-developed test. Directly competes with C2N's PrecivityAD2 by offering an alternative blood-based AD biomarker assay to the same healthcare provider and biopharma customer base.
- Fujirebio (H.U. Group Holdings): Fujirebio developed the Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio assay, the first FDA-cleared blood test for AD assessment. Directly competes with C2N in clinical blood-based AD diagnostics, with established IVD manufacturing scale and global distribution.
Broad incumbents
- Roche Diagnostics: Roche has launched Elecsys pTau217 blood-based AD assays as part of its broad diagnostics portfolio. While not specialized in neurology, Roche's massive installed base of immunoassay analyzers in hospital labs represents a significant competitive threat to specialty labs like C2N.
- Eli Lilly: Lilly is commercializing Kisunla (donanemab) for early symptomatic AD and is investing in companion diagnostics and blood-based biomarkers. As a vertically integrated pharma developing its own diagnostic strategy, Lilly is both a potential partner and a competitor for C2N's clinical trial and patient testing services.
- Sysmex: Sysmex developed an automated immunoassay platform for blood-based p-tau217 measurement (HISCL) and is expanding into clinical AD diagnostics in Japan and globally. Comparable to C2N as a blood-based AD test developer, with broader IVD scale but limited single-disease specialization.
- Eisai: Eisai is a strategic investor and partner in C2N ($15M partnership) and commercializes Leqembi (lecanemab) for early AD. As both a commercial partner and developer of companion diagnostics, Eisai is highly comparable to C2N's positioning in the AD ecosystem, with broader pharma scale.
- Biogen: Biogen developed Aduhelm and is a major AD therapeutics player with extensive investment in biomarker development. Operates in the same AD clinical ecosystem as C2N and is a potential pharma partner or acquirer for AD diagnostic capabilities.
- AbbVie: AbbVie partnered with C2N on the C2N-8E12 (ABBV-8E12) Phase 1 program for Progressive Supranuclear Palsy. As a large neuroscience-focused pharma with AD/PSP programs, AbbVie is both a current partner and a comparable player in neurodegenerative biomarker-driven drug development.
Emerging players
- SomaLogic: SomaLogic operates a SomaScan proteomics platform enabling large-scale biomarker discovery across multiple disease areas including neurodegeneration. Comparable to C2N in its use of advanced proteomic technology for biomarker discovery, though C2N is more clinically focused while SomaLogic serves primarily research customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
C2N Diagnostics social profiles
Digital presenceC2N Diagnostics compliance and trust
Trust signalCompliance7 records
C2N Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
C2N Diagnostics leadership team
Management profileNumber of profiles
Profiles4 records
C2N Diagnostics funding detail
Funding detailFunding overview
Funding rounds10 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
C2N Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about C2N Diagnostics
What does C2N Diagnostics do?
C2N Diagnostics develops and commercializes proprietary blood-based diagnostic tests for Alzheimer's disease and related neurodegenerative conditions using high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology. The core Precivity™ product line includes PrecivityAD®, PrecivityAD2™, and Precivity-ApoE™ clinical diagnostic tests, complemented by research-use-only tau assays (C2N eMTBR-tau243 and C2N %p-tau MAA) and bioanalytical services for pharmaceutical clinical trials. All clinical tests are processed in the company's CAP-accredited, CLIA-certified laboratory in St. Louis, Missouri, with global distribution through laboratory network and regional distribution partners.
Is C2N Diagnostics a public or private company?
C2N Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was C2N Diagnostics founded?
C2N Diagnostics was founded in 2007. It employs 101 to 250 people.
Where is C2N Diagnostics based?
C2N Diagnostics is headquartered in Saint Louis, United States, in the North America region.
How does C2N Diagnostics make money?
One revenue line is on record: clinical Laboratory Testing Services.
Who are C2N Diagnostics's main competitors?
Direct peers on record are Quanterix, ALZpath and Fujirebio (H.U. Group Holdings). Broad incumbents are Roche Diagnostics, Eli Lilly, Sysmex, Eisai, Biogen and AbbVie. SomaLogic is listed as an emerging player.
Does C2N Diagnostics have an API?
No public API is recorded for C2N Diagnostics.
What industry is C2N Diagnostics in?
C2N Diagnostics's product category is Neurological Diagnostics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 2835.